Table 2. Characteristics of patients at the time of ILRR (n = 104).
| Characteristics | Number | % |
|---|---|---|
| Time from primary surgery to ILRR | ||
| Median, range (month) | 35.7 (4.5–132.3) | |
| Time from ILRR to distant metastasis | n = 49 | |
| Median, range (month) | 17.9 (1.5–111.1) | |
| Location of ILRR | ||
| Breast | 56 | 53.8 |
| Surgery scar or chest wall | 13 | 12.5 |
| Regional lymph node | 35 | 33.7 |
| Histology | ||
| Ductal | 88 | 84.6 |
| Non-ductal | 16 | 15.4 |
| Subtype | ||
| HR+/HER2- | 35 | 33.7 |
| HER2+, irrespective of HR+/- | 36 | 34.6 |
| TNBC | 15 | 14.4 |
| Not checked | 18 | 17.3 |
| Surgical treatment | ||
| Mastectomy | 45 | 43.3 |
| Excision | 41 | 39.4 |
| Node dissection | 18 | 17.3 |
| Treatment of ILRR | ||
| Chemotherapy | 31 | 29.8 |
| Radiotherapy | 36 | 34.6 |
| Hormonal therapy | 47 | 45.2 |
ILRR, isolated locoregional recurrence; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, Triple negative breast cancer